Lestera Gimpelson News Today

Some Covid-19 vaccines safely and effectively used lipid nanoparticles (LNPs) to deliver messenger RNA to cells. A new MIT study shows that different nanoparticles could be used for a potential Alzheimer’s disease (AD) therapy. In tests in multiple m

In mice and human cell cultures, MIT researchers showed that lipid nanoparticles can deliver a potential RNA therapy for inflammation in the brain, a prominent symptom in Alzheimer’s disease.

<p>In mice and human cell cultures, MIT researchers showed that  novel nanoparticles can deliver a potential therapy for inflammation in the brain, a prominent symptom in Alzheimer’s disease</p>

A new candidate drug reduced inflammation and improved memory in human cell cultures and Alzheimer’s mouse models. The work was co-led by the lab of Li-Huei Tsai at the Picower Institute for Learning and Memory.

A potential new Alzheimer’s drug represses the harmful inflammatory response of the brain’s immune cells, reducing disease pathology, preserving neurons and improving cognition in preclinical tests.

A new study from MIT shows how a type of cells called microglia contribute to the slowdown of neuron activity seen in Alzheimer’s disease. The study found that microglia that express the APOE4 gene, one of the strongest genetic risk factors for Alzheimer’s disease, cannot metabolize lipids normally, leading to a buildup of excess lipids that interferes with nearby neurons’ ability to communicate with each other.